# US 2003/0211473 A1 · Cancer diagnostic method based upon DNA methylation differences

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0211473 A1
- Document ID: US20030211473A1
- Status: Published application
- Kind: A1
- Application number: 09/887,941
- Filed: 2001-06-22
- Published: 2003-11-13
- Earliest claimed: 1997-06-09
- Assignees: University of Southern California
- Inventors: Mark L. Gonzalgo; Peter A. Jones; Gangning Liang
- Web page: https://patentgrep.com/patent/US20030211473A1

## CPC

- C07H 21/00: Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C12Q 1/6827: for detection of mutation or polymorphism
- C12Q 1/6858: Allele-specific amplification
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

There is disclosed a cancer diagnostic method based upon DNA methylation differences at specific CpG sites. Specifically, the inventive method provides for a bisulfite treatment of DNA, followed by methylation-sensitive single nucleotide primer extension (Ms-SNuPE), for determination of strand-specific methylation status at cytosine residues.

## Claims

### Claim 1

A method for determining DNA methylation patterns at cytosine sites, comprising the steps of:
(a) obtaining genomic DNA from a DNA sample to be assayed;
(b) reacting the genomic DNA with sodium bisulfite to convert unmethylated cytosine residues to uracil residues while leaving any 5-methylcytosine residues unchanged to provide primers specific for the bisulfite-converted genomic sample for top strand or bottom strand methylation analysis;
(c) performing a PCR amplification procedure using the top strand or bottom strand specific primers;
(d) isolating the PCR amplification products;
(e) performing a primer extension reaction using Ms-SNuPE primers, [32P]dNTPs and Taq polymerase, wherein the Ms-SNuPE primers comprise a from about a 15 mer to about a 22 mer length primer that terminates immediately 5′ of a single nucleotide to be assayed; and
(f) determining the relative amount of allelic expression of CpG methylated sites by measuring the incorporation of different 32P-labeled dNTPs.

### Claim 2 (depends on 1)

The method of claim 1 wherein the [32P]dNTP for top strand analysis is [32P]dCTP or [32P]TTP.

### Claim 3 (depends on 1)

The method of claim 1 wherein the [32P]dNTP for bottom strand analysis is [32P]dATP or [32P]dGTP.

### Claim 4 (depends on 1)

The method of claim 1 wherein the isolation step of the PCR products uses an electrophoresis technique.

### Claim 5 (depends on 4)

The method of claim 4 wherein the electrophoresis technique uses an agarose gel.

### Claim 6 (depends on 1)

The method of claim 1 wherein the Ms-SNuPE primer sequence comprises a sequence of at least fifteen but no more than twenty five bases having a sequence selected from the group consisting of GaL1 [SEQ ID NO. 1], GaL2 [SEQ ID NO. 2], GaL4 [SEQ ID NO. 3], HuN1 [SEQ ID NO. 5], HuN2 [SEQ ID NO. 6], HuN3 [SEQ ID NO. 7], HuN4 [SEQ ID NO. 8], HuN5 [SEQ ID NO. 8], HuN6 [SEQ ID NO. 9], CaS1 [SEQ ID NO. 10], CaS2 [SEQ ID NO. 11], CaS 4 [SEQ ID NO. 12], and combinations thereof.

### Claim 7

A Ms-SNuPE primer sequence designed to anneal to and terminate immediately 5′ of a desired cytosine codon in a CpG target site, comprising an oligonucleotide sequence of at least 15 base pairs and corresponding to a gene sequence located immediately 5′ upstream from the CpG island that is frequently hypermethylated in promoter regions of somatic genes in malignant tissue.

### Claim 8

The Ms-SNuPE primer sequence wherein the primer sequence is from about 15 to about 25 base pairs in length and selected from the group consisting of GaL1 [SEQ ID NO. 1], GaL2 [SEQ ID NO. 2], GaL4 [SEQ ID NO. 3], HuN1 [SEQ ID NO. 5], HuN2 [SEQ ID NO. 6], HuN3 [SEQ ID NO. 7], HuN4 [SEQ ID NO. 8], HuN5 [SEQ ID NO. 8], HuN6 [SEQ ID NO. 9], CaS1 [SEQ ID NO. 10], CaS2 [SEQ ID NO. 11], CaS4 [SEQ ID NO. 12], and combinations thereof.

### Claim 9

A method for obtaining a Ms-SNuPE-primer sequence designed to anneal to and terminate immediately 5′ of a desired cytosine codon in the CpG target site, comprising finding a hypermethylated CpG island in a somatic gene from a malignant tissue or cell culture, determining the sequence located immediately 5′ upstream from the hypermethylated CpG island, and isolating a 15 to 25 mer sequence 5′ upstream from the hypermethylated CpG island for use as a Ms-SNuPE primer.

### Claim 10

A Ms-SNuPE primer comprising a 15 to 25 mer oligonucleotide sequence obtained by the process comprising, finding a hypermethylated CpG island in a somatic gene from a malignant tissue or cell culture, determining the sequence located immediately 5′ upstream from the hypermethylated CpG island, and isolating a 15 to 25 mer sequence 5′ upstream from the hypermethylated CpG island for use as a Ms-SNuPE primer.
